Diabetic nephropathy in American Indians, with a special emphasis on the pima Indians

Current Diabetes Reports

Volumn 8, Issue 6, 2008, Pages 486-493

  Pavkov, Meda E ^b   Knowler, William C ^b   Hanson, Robert L ^b   Nelson, Robert G ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLITAZONE DERIVATIVE; INSULIN; ORAL ANTIDIABETIC AGENT; RENIN INHIBITOR;

ALBUMINURIA; AMERICAN INDIAN; BLOOD PRESSURE REGULATION; COMORBIDITY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG CLEARANCE; DRUG MECHANISM; ETHNICITY; GENETIC ASSOCIATION; GLOMERULAR STRUCTURE; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INCIDENCE; KIDNEY DISEASE; KIDNEY FAILURE; MICROALBUMINURIA; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ONSET AGE; PERIODONTAL DISEASE; PIMA INDIAN; PODOCYTE; PRENATAL DISORDER; PRENATAL EXPOSURE; PREVALENCE; PROTEIN BLOOD LEVEL; RACE; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR;

ARIZONA; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; INCIDENCE; INDIANS, NORTH AMERICAN; KIDNEY DISEASES; MORBIDITY; PREVALENCE; UNITED STATES;

EID: 63149179807     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-008-0083-1     Document Type: Review

References (52)

1. Centers for Disease Control and Prevention: National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2007. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2008.
2. Xu J, Knowler WC, Devereux RB, et al.: Albuminuria within the "normal" range and risk of cardiovascular disease and death in American Indians: The Strong Heart Study. Am J Kidney Dis 2007, 49: 208-216.
3. Bella JN, Roman MJ, Fabsitz R, et al.: Association of albuminuria with systolic and diastolic left ventricular dysfunction in type 2 diabetes. The Strong Heart Study. J Am Coll Cardiol 2003, 41: 2022-2028.
4. Robbins DC, Knowler WC, Lee ET, et al.: Regional differences in albuminuria among American Indians: An epidemic of renal disease Kidney Int 1996, 49: 557-563.
5. Hirata-Dulas CA, Rith-Najarian SJ, McIntyre MC, et al.: Risk factors for nephropathy and cardiovascular disease in diabetic Northern Minnesota American Indians. Clin Nephrol 1996, 46: 92-98.
6. Sosenko JM, Dongsheng H, Welty T, et al.: Albuminuria in recent-onset type 2 diabetes. The Strong Heart Study. Diabetes Care 2002, 51: 1078-1084.
7. Scavini M, Shah VO, Stidley CA, et al.: Kidney disease among the Zuni Indians: The Zuni Kidney Project. Kidney Int Suppl 2005, 68: S126-S131.
8. Nelson RG, Kunzelman CL, Pettitt DJ, et al.: Albuminuria in type 2 (non-insulin-dependent) diabetes mellitus and impaired glucose tolerance in Pima Indians. Diabetologia 1989, 32: 870-876.
9. Hoehner CM, Greenlund KJ, Rith-Najarian S, et al.: Association of the insulin resistance syndrome and microalbuminuria among nondiabetic Native Americans. The Inter-Tribal Heart Project. J Am Soc Nephrol 2002, 13: 1626-1634.
10. U.S. Renal Data System: USRDS 2007 Annual Data Report. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007.
11. Pavkov ME, Bennett PH, Sievers ML, et al.: Predominant effect of kidney disease on mortality in Pima Indians with or without type 2 diabetes. Kidney Int 2005, 68: 1267-1274.
12. Young BA, Maynard C, Boyko EJ: Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of Veterans. Diabetes Care 2003, 26: 2392-2399.
13. Nelson RG, Bennett PH, Beck GJ, et al.: Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med 1996, 335: 1636-1642.
14. Lemley KV: A basis for accelerated progression of diabetic nephropathy in Pima Indians. Kidney Int 2003, 63(Suppl 83): S38-S42.
15. Eddy AA: Proteinuria and interstitial injury. Nephrol Dial Transplant 2004, 19: 277-281.
16. Becker JU, Hoerning A, Schmid KW, Hoyer PF: Immigrating progenitor cells contribute to human podocyte turnover. Kidney Int 2007, 72: 1468-1473.
17. Pagtalunan ME, Miller PL, Jumping-Eagle S, et al.: Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997, 99: 342-348.
18. Lemley KV, Abdullah I, Myers BD, et al.: Evolution of incipient nephropathy in type 2 diabetes mellitus. Kidney Int 2000, 58: 1228-1237.
19. Hanson RL, Elston RC, Pettitt DJ, et al.: Segregation analysis of non-insulin-dependent diabetes mellitus in Pima Indians: Evidence for a major-gene effect. Am J Hum Genet 1995, 57: 160-170.
20. McCance DR, HansAn RL, Pettitt DJ, et al.: Diabetic nephropathy: a risk factor for diabetes mellitus in offspring. Diabetologia 1995, 38: 221-226.
21. Hanson RL, Craig DW, Millis MP, et al.: Identification of PVT1 as a candidate gene for end-stage renal disease in type 2 diabetes using a pooling-based genome-wide single nucleotide polymorphism association study. Diabetes 2007, 56: 975-983.
22. Conrad DF, Jakobsson M, Coop G, et al.: A worldwide survey of haplotype variation and linkage disequilibrium in the human genome. Nat Genet 2006, 38: 1251-1260.
23. Iyengar SK, Abboud HE, Goddard KAB, et al.: Genome-wide scans for diabetic nephropathy and albuminuria in multiethnic populations: The Family Investigation of Nephropathy and Diabetes (FIND). Diabetes 2007, 56: 1577-1585.
24. Schelling JR, Abboud HE, Nicholas SB, et al.: Genome-wide scan for estimated GFR in multi-ethnic diabetic populations: The Family Investigation of Nephropathy and Diabetes. Diabetes 2008, 57: 235-243.
25. Nelson RG: Intrauterine determinants of diabetic kidney disease in disadvantaged populations. Kidney Int 2003, 83: S13-S16.
26. Tran S, Chen YW, Chenier I, et al.: Maternal diabetes modulates renal morphogenesis in offspring. J Am Soc Nephrol 2008, 19: 943-952.
27. Abrahamson DR, Steenhard BM: Perinatal nephron programming is not so sweet in maternal diabetes. J Am Soc Nephrol 2008, 19: 837-839.
28. Luyckx VA, Brenner BM: Low birth weight, nephron number, and kidney disease. Kidney Int 2005, 68: S68-S77.
29. Nelson RG, Knowler WC, Pettitt DJ, et al.: Incidence and determinants of elevated urinary albumin excretion in Pima Indians with NIDDM. Diabetes Care 1995, 18: 182-187.
30. Nelson RG, Pettitt DJ, de Courten MP, et al.: Parental hypertension and proteinuria in Pima Indians with NIDDM. Diabetologia 1996, 39: 433-438.
31. Nelson RG, Pettitt DJ, Baird HR, et al.: Pre-diabetic blood pressure predicts urinary albumin excretion after the onset of type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians. Diabetologia 1993, 36: 998-1001.
32. Knowler WC, Pettitt DJ, Saad MF, Bennett PH: Diabetes mellitus in the Pima Indians: Incidence, risk factors and pathogenesis. Diabetes Metab Rev 1990, 6: 1-27.
33. Pavkov ME, Hanson RL, Knowler WC, et al.: Changing patterns of type 2 diabetes incidence among Pima Indians. Diabetes Care 2007, 30: 1758-1763.
34. Pavkov ME, Bennett PH, Knowler WC, et al.: Effect of youthonset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. JAMA 2006, 296: 421-426.
35. Krakoff J, Lindsay RS, Looker HC, et al.: Incidence of retinopathy and nephropathy in youth-onset compared with adult-onset type 2 diabetes. Diabetes Care 2003, 26: 76-81.
36. Shultis WA, Weil EJ, Looker HC, et al.: Effect of periodontitis on overt nephropathy and end-stage renal disease in type 2 diabetes. Diabetes Care 2007, 30: 306-311.
37. Burrows NR, Li Y, Williams DE: Racial and ethnic differences in trends of end-stage renal disease: United States, 1995 to 2005. Adv Chronic Kidney Dis 2008, 15: 147-152.
38. Narva AS: Reducing the burden of chronic kidney disease among American Indians. Adv Chronic Kidney Dis 2008, 15: 168-173.
39. Pavkov ME, Knowler WC, Bennett PH, et al.: Increasing incidence of proteinuria and declining incidence of end-stage renal disease in diabetic Pima Indians. Kidney Int 2006, 70: 1840-1846.
40. Pavkov ME, Knowler WC, Hanson RL, et al.: Predictive power of sequential measures of albuminuria for progression to ESRD or death in Pima Indians with type 2 diabetes. Am J Kidney Dis 2008, 51: 759-766.
41. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [no authors listed]. Lancet 1998, 352: 837-853.
42. Miyazaki Y, Cersosimo E, Triplitt C, DeFronzo RA: Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney Int 2007, 72: 1367-1373.
43. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The ADVANCE Collaborative Group [no authors listed]. N Engl J Med 2008, 358: 2560-2572.
44. Viberti G, Wheeldon NM: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Circulation 2002, 106: 672-678.
45. Schrier RW, Estacio RO, Esler A, Mehler P: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes Kidney Int 2002, 61: 1086-1097.
46. Mauer M, Zinman B, Gardiner R, et al.: The renin-angiotensin system study (RASS): Effects of enalapril and losartan on diabetic nephropathy and diabetic retinopathy in normotensive, normoalbuminuric patients with type 1 diabetes mellitus. Presented at the American Diabetes Association 68th Scientific Sessions. San Francisco, CA; June 6-10, 2008.
47. Ruggenenti P, Fassi A, Ilieva AP, et al.: Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004, 351: 1941-1951.
48. Brenner BM, Cooper ME, DeZeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345: 861-869.
49. Mogensen CE, Neldam S, Takkanen I, et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and noninsulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000, 321: 1440-1444.
50. Telmisartan, Ramipril, or both in patients at high risk for vascular events. The ONTARGET Investigators [no authors listed]. N Engl J Med 2008, 358: 1547-1559.
51. Parving HH, Persson F, Lewis JB, et al.: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358: 2433-2446.
52. Gæde P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358: 580-591.